Effect of Azilsartan on Atrial Fibrillation in Patients With Hypertension

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.

Also called NCT05841654

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 400 participants (planned count) (from the registry)
Sponsor
Beijing Tsinghua Chang Gung Hospital (from the registry)
Registry
  • NCT NCT05841654
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05841654. Randomized; single masking; primary purpose prevention. Start 2023-06-01 (anticipated); primary completion 2025-06-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Azilsartan on Atrial Fibrillation in Patients With Hypertension
Acronym
AZAF
Condition
Hypertension
Intervention (Drug)
Azilsartan or antihypertensive drugs other than ACEI, ARB or ARNI
Lead sponsor
Beijing Tsinghua Chang Gung Hospital (class: other)

Record details

Record id
cardio:ct-nct05841654
Content hash
6b765f27b93cb291f6b406998e774bf4e135894e76ba8c8ceeba921a1b897d9c